Axa's Buyback and Strategy Reset Collide With Courtroom Setback and ICC Exit

Axa's stock fell 5.5% over a week as the ICC health insurance contract ended and a London appeal reversed a PPI payout, testing its 'Growing Forward' plan.

Axa finds itself navigating a crowded field of challenges, from a courtroom reversal in London to the quiet dissolution of a high-profile international mandate, all while management tries to sell investors on a multi-year growth blueprint that has yet to win over the market.

The French insurer's shares settled at EUR 41.96 on Friday, leaving the stock 8.6% below its 52-week high of EUR 45.89. Over a seven-day stretch the decline amounts to 5.5%, though the price still sits 1.1% above its 200-day moving average. European insurance names broadly came under pressure, but Axa's specific headwinds have given traders additional reason for caution.

A Contract Ends, and a Legal Battle Slips Away

Two separate developments have reshaped the company's risk map in recent weeks. The International Criminal Court and Axa mutually agreed to terminate their health insurance contract, according to media reports and Reuters. The exit is tied to concerns that US sanctions could be applied extraterritorially — a worry that has made European financial groups increasingly wary of geopolitical entanglements.

On the legal front, the Court of Appeal in London ruled in favor of Santander Cards UK and Santander Insurance Services UK in a dispute over payment protection insurance. The decision overturned an earlier judgment that had awarded compensation to Axa France. The judges held that a contractual indemnity clause could not be applied retroactively to earlier periods.

Restructuring in the UK Proceeds Quietly

Meanwhile, Axa confirmed structural adjustments in its British operations on Tuesday. Following the merger of the UK retail and corporate customer units, 58 roles are affected. The company said it expects nearly all impacted employees to move into newly created positions. The consolidation forms part of a broader effort to streamline operational processes and strengthen efficiency across divisions.

The "Growing Forward" Plan and Its Price Tag

Roughly two weeks ago, Axa unveiled its medium-term strategic plan, "Growing Forward." Since that presentation, the stock has retreated — by 3.2% according to one measure, and by 5.1% according to another, depending on the reference point. Management is targeting average annual growth in adjusted earnings per share of 7% to 9%, alongside an adjusted return on equity of 15% to 17% for the 2027–2029 period. For the 2026 fiscal year, the company has signaled it expects to reach the upper end of both target ranges.

To offset dilution from its employee share ownership program, Axa has arranged a buyback and cancellation of its own shares worth up to EUR 470.8 million. The transactions are scheduled to conclude no later than October 29, 2026. The plan also includes a total payout ratio of 75%.

Analyst Support Holds Despite the Slide

Despite the recent weakness, major research houses remain largely constructive. Berenberg reaffirmed its buy rating about two weeks ago; the stock has since lost 4.5%. On September 25, RBC Capital analyst Ben Cohen maintained an "Outperform" rating with a price target of EUR 52.

Investors now await the release of Axa's activity indicators for the first nine months of fiscal 2026, due on October 29, 2026 — the same date the buyback window closes. That report will serve as the next significant checkpoint for gauging whether the "Growing Forward" targets are gaining traction.